NetraMark Holdings Inc. (TSX:AIAI)
Canada · Delayed Price · Currency is CAD | Market Cap | 66.24M -44.7% |
| Revenue (ttm) | 605.97K +21.9% |
| Net Income | -6.49M |
| EPS | -0.07 |
| Shares Out | 94.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,500 |
| Open | 0.6900 |
| Previous Close | 0.6600 |
| Day's Range | 0.6900 - 0.7200 |
| 52-Week Range | 0.5900 - 1.4000 |
| Beta | 1.40 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Jan 15, 2027 |
About NetraMark Holdings
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada. [Read more]
Financial Performance
In fiscal year 2025, NetraMark Holdings's revenue was 432,495, a decrease of -5.18% compared to the previous year's 456,127. Losses were -5.22 million, 56.7% more than in 2024.
Financial StatementsNews
NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright's AI-Based Drug Discovery and Development Conference
TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical tr...
NetraMark Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference
NetraAI leverages proprietary AI to identify subgroups in clinical trial data, improving trial design and success rates, especially in CNS and oncology. The technology is validated by FDA engagement, peer-reviewed publications, and major institutional collaborations, targeting a CAD 10 billion market with high margins and a dual commercialization strategy.
Peer-Reviewed Study Published in MDPI's AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models
NetraAI's biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested The study showed improved performance across convent...
NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor
Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc.
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical tr...
NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical tr...
NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High
TORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc . (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical...
NetraMark Holdings MD&A: Q3 2026
NetraMark Holdings filed a regulatory document on August 13, 2026 disclosing important business information.
NetraMark Holdings Report: Q3 2026
NetraMark Holdings published a report on August 13, 2026 containing material business information for investors and shareholders.
NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness
Collaboration intended to support broader awareness of NetraMark's clinical development initiatives and NetraAI platform Collaboration intended to support broader awareness of NetraMark's clinical dev...
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
New agreement is a significant commercial milestone and the Company's first with its contract research organization partner Agreement expands NetraMark's portfolio of AI-driven projects in central ner...
NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company
TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) company that is transform...
NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tra...
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry Company to particip...
NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is tran...
NetraMark Holdings Report: Q2 2026
NetraMark Holdings published a report on May 14, 2026 containing material business information for investors and shareholders.
NetraMark Holdings MD&A: Q2 2026
NetraMark Holdings filed a regulatory document on May 14, 2026 disclosing important business information.
NetraMark Holdings Earnings release: Q2 2026
NetraMark Holdings released its earnings on May 14, 2026, summarizing the period's financial results.
NetraMark Announces Change To Board Of Directors
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformin...
NetraMark Holdings Inc. (AIAI) Opens the Market
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - George Achilleos, Chief Executive Officer, NetraMark Holdings Inc. ("NetraMark", or the "Company") (TSX: AIAI) and their executive team, joined Dani ...
NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transformin...
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence so...
NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transform...
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transform...
Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and explainable AI for trial design in psychedelic clinical development. TORONTO, April 09, ...